Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose‐response study
Alimentary Pharmacology & Therapeutics2018Vol. 47(8), pp. 1162–1169
Citations Over TimeTop 10% of 2018 papers
Rémy Schwarzer, Danijel Kivaranovic, Rafael Paternostro, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Markus Peck‐Radosavljevic, Arnulf Ferlitsch
Abstract
Carvedilol 12.5 mg/d was more effective than 6.25 mg/d in decreasing HVPG in primary prophylaxis. A total of 76% of patients achieved a HVPG-response of ≥ 10% to carvedilol 12.5 mg/d, however, arterial hypotension might occur, especially in patients with ascites.
Related Papers
- → Usefulness of Serum N-terminal–ProBNP in Distinguishing Ascites Due to Cirrhosis From Ascites Due to Heart Failure(2009)26 cited
- → Evaluation of Carvedilol for the Treatment of Portal Hypertension(2004)26 cited
- → Frequency of Spontaneous Bacterial Peritonitis in Patients of Liver Cirrhosis with Ascites at Tanta University Hospitals(2019)3 cited
- Discussion of relationship between levels of CA125,CA199 and AFP and cirrhosis ascites(2006)
- → Brief Review of Portal Hypertension Related Complications(2021)